SUBSCRIBE
SUBSCRIBE

Newleos Therapeutics

NEWS
NextGen
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye.
January 7, 2026
 · 
2 min read
 · 
Annalee Armstrong
Art collage, hands and falling coins in orange circle. Modern design of finance and business.
Neuropsychiatric disorders
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche
Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
February 13, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
AWARDS
  • NextGen Class of 2026 Badge
JOBS
IN THE PRESS
Press Releases
Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder
January 6, 2026
 · 
6 min read
Press Releases
Newleos Therapeutics Appoints Timothy Noyes as President and Chief Executive Officer
October 21, 2025
 · 
4 min read
Press Releases
Newleos Therapeutics Announces Clinical Progress Across Neuropsychiatric Pipeline
October 1, 2025
 · 
6 min read
Press Releases
Newleos Therapeutics Appoints Stephen Brannan to Board of Directors and Announces NTX-1955 Clinical Progress in Generalized Anxiety Disorder
July 23, 2025
 · 
6 min read
Press Releases
Newleos Therapeutics Announces Clinical Advisory Board to Support Key Neuropsychiatry Programs
April 29, 2025
 · 
4 min read
Press Releases
Newleos Therapeutics Expands Leadership Team to Advance its Clinical-Stage Neuropsychiatric Programs and Drive Corporate Growth
April 8, 2025
 · 
3 min read
Press Releases
Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines
February 13, 2025
 · 
8 min read